Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
TargetMol | Tags GPCR/G Protein
TargetMol | Tags Neuroscience

P2Y Receptor

P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as adenosine triphosphate, adenosine diphosphate, uridine triphosphate, uridine diphosphate, and UDP-glucose.To date, 8 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14. P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y receptors mediate responses including vasodilation, blood clotting, and immune response. Due to their ubiquity and variety in function, they are a common biological target in pharmacological development.

PPTN hydrochloride
T635341992047-65-0In house
PPTN hydrochloride is a potent, high-affinity, competitive, and highly selective P2Y14 receptor antagonist (KB: 434 pM) with no agonist or antagonist activity at P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors, exhibiting anti-inflammatory and anti-immune effects.
  • $41
In Stock
Size
QTY
PSB-16133 sodium
T284632089035-40-3In house
PSB-16133 sodium is a selective P2Y purine receptor variant antagonist with an IC of 233 nM.
  • $293 TargetMol
In Stock
Size
QTY
Uridine 5′-diphosphoglucose disodium salt
T474328053-08-9
Uridine 5′-diphosphoglucose disodium salt (UDP-Glucose sodium salt) is an endogenous nucleotide sugar involved in glycosyltransferase reactions in metabolism. It is an agonist of the P2Y14 receptor (EC50 = 0.35 μM) and can also bind to and activate GPR17, inducing oligodendrocyte differentiation at a maximal concentration of 100 μM.
  • $42
In Stock
Size
QTY
BPTU
T4132870544-59-5
BPTU (BMS-646786) is an allosteric antagonist of P2Y1 (EC50 = 0.06-0.3 μM). Non-nucleotide ligand. Binds receptor outside of the helical bundle. Blocks inhibition of spontaneous contraction of rat and mouse colon induced by electrical field stimulation, nicotine and P2Y agonists. Antithrombotic; reduces platelet aggregation.
  • $32
In Stock
Size
QTY
TargetMol | Citations Cited
cangrelor tetrasodium
T5036163706-36-3
Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects.
  • $39
In Stock
Size
QTY
MRS 2578
T6172711019-86-2
MRS2578, an effective P2Y6 receptor antagonist with IC50 of 37 nM, shows insignificant inhibition at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
  • $38
In Stock
Size
QTY
Ticagrelor
T0179274693-27-5
Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).
  • $30
In Stock
Size
QTY
Clopidogrel hydrogen sulfate
T0182L120202-66-6
Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation.
  • $30
In Stock
Size
QTY
PPTN
T125301160271-30-6In house
PPTN is a high-affinity, competitive and highly selective antagonist of P2Y14 receptor(KB value of 434 pM), with anti-inflammatory and immune activity.
  • $42
In Stock
Size
QTY
Uridine-5'-diphosphate disodium salt
T470627821-45-0
Uridine-5'-diphosphate disodium salt (UDP disodium salt) is a specific agonist of the P2Y6 receptors (EC50 = 13 nM for human P2Y6), stimulating the production of inflammatory mediators, phagocytosis, and vasoconstriction. Uridine-5'-diphosphate disodium salt also acts as an antagonist of P2Y14.
  • $32
In Stock
Size
QTY
TargetMol | Citations Cited
Diquafosol tetrasodium
T7423211427-08-6
Diquafosol Tetrasodium is a P2Y2 receptor agonist that stimulates the secretion of mucins from ocular tissues Diquafosol tetrasodium (INS365) improves tear film stability and visual function, as a topical treatment of dry eye disease.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Prasugrel
T0230150322-43-3
Prasugrel (CS-747) is a piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
  • $35
In Stock
Size
QTY
Clopidogrel
T0182113665-84-2
Clopidogrel (SR-25990C), a P2Y12 receptor antagonist, decreases platelet aggregation.
  • $41
In Stock
Size
QTY
Elinogrel
T11177936500-94-6In house
Elinogrel (PRT060128) is a competitive and reversible antagonist of platelet P2Y12 with IC50 of 20 nM and exhibits potent antiplatelet effects.
  • $51
In Stock
Size
QTY
AZD1283
T3536919351-41-0
AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug kg min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg kg min, respectively. The doses induced the increase in bleeding time at 33 and 100 μg kg min for 3- and 13-fold, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds.
  • $31
In Stock
Size
QTY
PIT
T2316456583-49-4
PIT (2,2'-Pyridylisatogen tosylate) is a specific, non-competitive antagonist of the Purinergic receptor P2Y1, exhibiting an IC50 of 0.14 μM for human P2Y1. It does not affect nucleotide binding and is useful in studies related to chronic bronchitis and asthma.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Clopidogrel thiolactone
T55011147350-75-1
Clopidogrel thiolactone (2-oxoclopidogrel) is a potent P2Y12 receptor inhibitor and a potent antiplatelet aggregation compound.Clopidogrel thiolactone is the active metabolic intermediate resulting from the first oxidative activation of Clopidogrel.
  • $98
In Stock
Size
QTY
Prasugrel Hydrochloride
T6952389574-19-0
Prasugrel Hydrochloride (LY 640315 Hydrochloride) is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.
  • $30
In Stock
Size
QTY
(±) Clopidogrel hydrogen sulfate
T0182L2135046-48-9
(±) Clopidogrel hydrogen sulfate (Iscover) , an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease.
  • $50
In Stock
Size
QTY
N6-(4-Hydroxybenzyl)adenosine
T12164110505-75-4In house
N6-(4-Hydroxybenzyl)adenosine (Para-topolin riboside) is a platelet aggregation inhibitor.
  • $40
In Stock
Size
QTY
Regrelor disodium
T34280676251-22-2In house
Regrelor disodium (INS 50589) is a P2Y12 receptor antagonist that prevents thrombosis, effectively inhibits vascular smooth muscle cell contraction, curbs cell proliferation, and reduces inflammation.
  • $117
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ticagrelor metabolite M5
T210591251765-07-7
Ticagrelor metabolite M5 (T437700) is a metabolite of Ticagrelor, the first reversible oral antagonist of P2Y12 receptor. Compared to Clopidogrel, Ticagrelor has faster and more consistent inhibition on ADP-receptors. Ticagrelor is used in the treatment of acute coronary syndromes (ACS).
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
1-[(5-methylisoxazol-3-yl)methyl]piperazine
T8582173850-51-6
1-[(5-methylisoxazol-3-yl)methyl]piperazine (Piperazine, 1-[(5-methyl-3-isoxazolyl)methyl]-) is a P2Y12 inhibitor.
  • $80
In Stock
Size
QTY
TargetMol | Inhibitor Sale
HDL-16
T865652373280-36-3
HDL-16 is a highly effective P2Y14R antagonist with anti-colitis effects, targeting P2Y14R in intestinal epithelial cells to alleviate ulcerative colitis.
  • $30
In Stock
Size
QTY
PSB-0739
T231951052087-90-7
PSB-0739 Selective platelet P2Y12 receptor antagonist characterized by competitive binding and high affinity (Ki =24.9 nM) with antithrombotic and platelet aggregation modulating effects.
    Inquiry
    Selatogrel
    T713641159500-34-1
    Selatogrel (ACT-246475) is a selective and potent P2Y12 receptor antagonist with antithrombotic activity and inhibition of platelet aggregation for the study of acute myocardial infarction.
    • $98
    In Stock
    Size
    QTY
    ym-254890
    T17273568580-02-9
    YM-254890, a macrocyclohexapeptide isolated from Chromobacterium sp, is a selective and potent inhibitor of Gαq 11 protein, inhibits ADP-induced platelet aggregation and inhibits G protein signaling.
    • $1,199
    35 days
    Size
    QTY
    TargetMol | Inhibitor Hot
    ATP-γ-S tetrasodium
    T8382788453-52-5
    ATP-γ-S tetrasodium (Adenosine-5'-O-(3-thiotriphosphate) tetrasodium) is a purinergic P2Y11 receptor agonist and ATP analog that induces inositol phosphate accumulation, induces insulin secretion from MIN6 pancreatic islet β-cells, and induces an increase in intracellular calcium concentration. ATP-γ-S tetrasodium inhibits the induction of the Junin virus. Junin virus-induced increase in the level of mRNA encoding bone morphogenetic protein 6 (BMP6) reduces particle-forming units (PFUs) in Junin virus-infected primary rat osteoblasts.
    • $398
    35 days
    Size
    QTY
    2-Methylthioadenosine diphosphate trisodium
    T23581475193-31-8
    2-Methylthioadenosine diphosphate trisodium (2-MeS-ADP) is the salt form of 2-Methylthioadenosine diphosphate, a synthetic analog of adenosine diphosphate (ADP), a potent purinergic P2Y receptor agonist that agonizes human P2Y13 at nanomolar levels, mouse P2Y13 and human P2Y12, induces platelet aggregation and morphological changes, and is indicated for neurological and cardiovascular disease studies.
    • $143
    35 days
    Size
    QTY
    SYL-4
    T836376222-65-7In house
    SYL-4 is a potential P2Y12 receptor antagonist with a Ki value of 7.35 ± 1.72 for use in synthetic dyes.
    • $882
    In Stock
    Size
    QTY
    2-Methylthio-ATP tetrasodium
    T22496100020-57-3
    2-Methylthio-ATP tetrasodium (2-MeS-ATP tetrasodium) is a non-specific P2 receptor agonist, which can activate P2X2 and P2Y1 receptors and mimic the physiological effects of ATP by binding to P2 receptors, and is widely used in the study of cell signaling and metabolic processes. In addition, 2-Methylthio-ATP tetrasodium induces non-competitive inhibition of ADP-induced platelet aggregation in human.
    • $253
    35 days
    Size
    QTY
    P2Y14 antagonist 1
    T205734
    P2Y14 antagonist 1 (compound 45) is a highly selective and orally active P2Y14 receptor antagonist with an IC50 value of 0.70 nM. It demonstrates significant anti-inflammatory effects by effectively reducing pulmonary infiltration of immune cells and inflammatory responses through the inhibition of the NLRP3 signaling pathway. P2Y14 antagonist 1 is suitable for studying acute lung injury.
    • Inquiry Price
    Size
    QTY
    Uridine 5'-diphosphate
    T7858358-98-0
    Uridine 5'-diphosphate acts as a P2Y6 receptor agonist, exhibiting an EC50 value of 0.013 μM for the human P2Y6 receptor [1].
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    4-Thiouridine 5′-triphosphate tetralithium
    T7919620188-72-1
    4-Thiouridine 5′-triphosphate tetralithium (4-Thio-UTP), a potent P2Y2 and P2Y4 receptor agonist, exhibits EC50 values of 35 nM for hP2Y2 and 350 nM for hP2Y4. It is utilized in crosslinking experiments and labeling of transcriptional complexes [1] [2].
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    NF546 hydrate
    T78079
    NF546 (hydrate), a selective non-nucleotide P2Y11 agonist, exhibits a pEC50 value of 6.27 and induces interleukin-8 secretion from human monocyte-derived dendritic cells [1].
    • Inquiry Price
    Size
    QTY
    4-Thiouridine 5′-triphosphate disodium
    T7919768507-49-3
    4-Thiouridine 5′-triphosphate (4-Thio-UTP) tetrasodium functions as a potent agonist at P2Y 2 and P2Y 4 receptors, with half-maximal effective concentrations (EC50s) of 35 nM for hP2Y 2 and 350 nM for hP2Y 4. This compound is applicable in studies involving crosslinking experiments and labeling of the transcriptional complex [1] [2].
    • Inquiry Price
    Size
    QTY
    MRS2905 trisodium
    T2046873033550-04-5
    MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective P2Y14R agonist with an EC50 of 0.92 nM. It shows no activity on UDP-activated P2Y6 receptors or other P2Y receptors.
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    NSC380324
    T205528
    NSC380324 is a P2Y12 receptor antagonist with antiplatelet properties, which can be employed in research on atherosclerotic cardiovascular diseases.
    • Inquiry Price
    Size
    QTY
    MRS4833
    T2008372801627-78-9
    MRS4833 (compound 15) is an orally active, potent, competitive antagonist of P2Y14R, exhibiting IC50 values of 5.92 nM for hP2Y14R and 4.8 nM for mP2Y14R. It reduces airway eosinophilia in protease-mediated asthma models and reverses chronic neuropathic pain in mouse CCI models.
    • Inquiry Price
    3-6 months
    Size
    QTY
    P2Y6R antagonist 1
    T200515
    P2Y6R antagonist 1 (compound 5ab) is a selective, orally active antagonist of P2Y6R, featuring an IC50 value of 19.6 nM. This compound also exhibits anti-inflammatory properties.
    • Inquiry Price
    Size
    QTY
    P2Y14R antagonist 3
    T205281
    P2Y14R antagonist 3 (compound A) is an orally active P2Y14R antagonist with an IC50 of 23.60 nM and a Kd of 7.26 μM. It mitigates lung injury in mice induced by Lipopolysaccharides (LPS) and can be utilized in the study of inflammatory diseases.
    • Inquiry Price
    Size
    QTY
    PSB-1114 triethylamine
    T78080
    PSB-1114 triethylamine is a potent, enzymatically stable, P2Y2 receptor agonist with a 134 nM EC50, exhibiting greater than 50-fold selectivity over P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors [1].
    • Inquiry Price
    Size
    QTY